Rifapentine Tablets Shortage

• • Priftin oral tablet, Sanofi-Aventis, 150 mg, 24 count, NDC 00088-2102-24

• • Sanofi did not provide a reason for the shortage.
  • Sanofi is the sole supplier of rifapentine tablets.

• • There is insufficient supply for usual ordering

Estimated Resupply Dates

• • Sanofi has Priftin 150 mg tablets in 24 count unit-dose packages on allocation.

Implications for Patient Care

• • Rifapentine is an oral tablet used in combination with isoniazid to treat latent tuberculosis (TB) caused by Mycobacterium tuberculosis in patients aged 2 years and older. It is also used with one or more anti-tuberculosis drugs to treat active TB in patients 12 years and older.[1-2]

Alternative Agents & Management

• • Guidelines for special populations and drug-resistant TB can be found in this recent update. Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline | American Journal of Respiratory and Critical Care Medicine.[3]
  • Examples of alternate treatment regimens that do not include rifapentine are listed below.[3-5]
  • For latent tuberculosis:
  • 1. Daily rifampin for 4 months
  • 2. Daily isoniazid plus rifampin for 3 months.
  • 3. An alternative regimen consists of daily isoniazid for 6 to 9 months.
  • For active tuberculosis:
  • 1. Isoniazid, rifampin, pyrazinamide, and ethambutol. The specific duration and dosing interval depend on the selected regimen.

References

• 1. Rifapentine [package insert]. DailyMed. Published August 2021. Accessed March 27, 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3882444-18ca-4708-a51b-6c089664c10c
  2. Rifapentine. Lexi-Drug Online. Wolters Kluwer Clinical Drug Information. Hudson, Ohio, USA. Accessed; Accessed March 27, 2025.
  3. Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline | American Journal of Respiratory and Critical Care Medicine
  4. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. MMWR Recomm Rep. 2020;69(RR-1):1-83. Accessed March 27, 2025. https://www.cdc.gov/mmwr/volumes/69/rr/rr6901a1.htm?s_cid=rr6901a1_w
  5. Infectious Diseases Society of America. Treatment of Drug-Susceptible Tuberculosis. Accessed March 27, 2025. https://www.idsociety.org/practice-guideline/treatment-of-drug-susceptible-tb/